--Starbucks Q4 Global Comparable Store Sales Decline 7%; Revenue at $9.1 Billion, vs CIQ Analyst Consensus of $9.4 Billion-March 2024-www.financetom.com

--Starbucks Q4 Global Comparable Store Sales Decline 7%; Revenue at $9.1 Billion, vs CIQ Analyst Consensus of $9.4 Billion

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Starbucks Q4 Global Comparable Store Sales Decline 7%; Revenue at $9.1 Billion, vs CIQ Analyst Consensus of $9.4 Billion

Oct 22, 2024 1:31 PM

04:07 PM EDT, 10/22/2024 (MT Newswires) --

Price: 96.81, Change: -0.01, Percent Change: -0.01

Previous page： Online university American Public Education's Q3 revenue beats estimates Next page： Tulip grower Lendway's Q3 net revenue falls

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Online university American Public Education's Q3 revenue beats estimates

Nov 10, 2025

Overview * American Public Education ( APEI ) Q3 revenue grows 7% yr/yr, beating analyst expectations * Net income for Q3 rises 660% yr/yr to $5.6 mln * Adjusted EBITDA for Q3 increases 60% to $20.7 mln Outlook * Company expects Q4 2025 revenue between $150 mln and $153.5 mln, down 6% to 9% * Company sees full-year 2025 revenue...

Tulip grower Lendway's Q3 net revenue falls

Nov 10, 2025

Overview * Lendway Q3 2025 net revenue falls to $5.2 mln from $6.6 mln in Q3 2024 * Company's Q3 2025 operating loss widens to $3.0 mln from $1.4 mln in Q3 2024 * Net loss attributable to Lendway increases to $2.9 mln from $1.1 mln in Q3 2024 Outlook * Lendway ( LDWY ) expects revenue to increase in...

Terns Pharmaceuticals posts narrower than expected Q3 net loss

Nov 10, 2025

Overview * Terns reports Q3 net loss of $24.6 mln, less than analysts' expectations * Company highlights promising Phase 1 CARDINAL trial results for TERN-701 in CML * Terns shifts focus to oncology, seeks partners for metabolic programs Outlook * Company expects cash reserves to support operations into 2028 * Terns to present expanded CARDINAL trial data at ASH meeting...

Spine implant maker SI-BONE's Q3 revenue beats estimates

Nov 10, 2025

Overview * SI-BONE ( SIBN ) Q3 revenue grows 20.6% yr/yr, beating analyst expectations * Net loss for Q3 improves by 30.6% to $4.6 mln * Adjusted EBITDA turns positive at $2.3 mln in Q3 Outlook * SI-BONE ( SIBN ) expects 2025 revenue between $198 mln and $200 mln, up from prior $195 mln to $198 mln * Company...